WATCH LIVE
timothy sykes logo
OSCR Stock Rallies As Barclays Targets Aggressive Upside Thumbnail
G Google News

OSCR Stock Rallies As Barclays Targets Aggressive Upside

TIM SYKES•UPDATED JUL. 1, 2026, 5:03 PM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

Oscar Health Inc. stocks have been trading up by 11.33 percent, driven by optimistic sentiment around its healthcare technology growth prospects.

Key Takeaways

  • Barclays upgraded Oscar Health to Overweight and lifted its target to $35, calling out ACA pure-play exposure, margin recovery, and an undemanding valuation versus peers.
  • The $35 Barclays target for Oscar Health sits far above the Street’s $22.64 average, while most firms still rate OSCR a Hold.
  • Wells Fargo boosted OSCR from Underweight to Equal Weight, doubling its target from $11 to $20 on stronger 2026 exchange expectations but flagged limited visibility beyond 2026.
  • Shares of Oscar Health ripped 12%–15% in early June, pushing OSCR into the low-$20s on strong momentum and short-term buying.
  • Co-founder Mario Schlosser is leaving the CTO role at Oscar Health to advise the CEO while remaining on the board.

Candlestick Chart

Live Update At 17:03:24 EDT: On Wednesday, July 01, 2026 Oscar Health Inc. stock [NYSE: OSCR] is trending up by 11.33%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Oscar Health, ticker OSCR, has turned into a textbook momentum story backed by improving fundamentals. The stock has pushed from the mid-$20s to around $31.90 recently, with the daily chart showing a steady series of higher lows from 2026/06/08 onward. For short-term traders, that staircase pattern often signals aggressive dip buying and strong conviction.

On the tape, OSCR trades in a relatively tight intraday range, with the most recent session holding between roughly $29 and $32 before closing near the highs. That late-day push from about $31.40 to just under $32 shows buyers in control into the close, a key sign for momentum traders looking for follow-through the next morning.

More Breaking News

Fundamentally, Oscar Health is starting to back up the chart. Quarterly revenue is about $4.65B, with annualized revenue over $11.7B. The company still shows slightly negative profit margins on a trailing basis, but the latest quarter delivered roughly $679M in net income and more than $2.6B in free cash flow. OSCR’s price-to-sales ratio near 0.42 and price-to-cash-flow around 0.5 suggest the market is not pricing it like a high-flying growth story yet, which is exactly what many active traders like to see when momentum wakes up.

Why Traders Are Watching OSCR Now

OSCR has moved from a quiet recovery name to a live-wire trading vehicle after a powerful run sparked by major analyst upgrades. The big catalyst: Barclays shifted Oscar Health to Overweight from Equal Weight and took its price target to $35. That call leans hard into OSCR as a pure-play on the individual Affordable Care Act market, arguing margins should recover as pricing resets and that the stock still trades at the low end of peer valuations despite strong long-term leverage in the business.

For traders, that’s classic “re-rating” fuel. When a heavyweight like Barclays plants a $35 target while the stock trades in the low $30s and the Street average sits around $22.64, it highlights a gap between where one influential bank thinks Oscar Health belongs and where consensus is still parked. If other firms chase that view higher, OSCR can see more upgrades and headline momentum, which often brings in fresh trading volume.

Earlier in June, Wells Fargo laid the groundwork by moving OSCR from Underweight to Equal Weight and hiking its target from $11 to $20. That signaled that even the skeptics were backing off. Wells Fargo did flag limited visibility beyond 2026 and highlighted payment integrity as a key focus, so it was not a full-on bull call. But for traders, the shift from “avoid” to “neutral” can be enough to flip sentiment.

Price action confirmed the turn. OSCR spiked 12% to about $22.99 and then as much as 15% intraday to $23.58 in early June, at times without fresh fundamental news. That tells traders the stock has moved into a momentum phase where upgrades, reratings, and short-covering drive sharp squeezes. The leadership change, with co-founder Mario Schlosser stepping out of the CTO role to become adviser to the CEO while staying on the board, adds a governance headline but doesn’t change the trading story materially. The tech DNA remains in-house, which should matter to longer-term players, while short-term traders stay locked on the chart.

Conclusion

Right now, OSCR sits at the intersection of solid numbers, improving sentiment, and powerful momentum — the mix active traders scan for every day. Oscar Health has turned a corner on profitability, with hundreds of millions in quarterly net income and strong operating cash flow, while still wearing a valuation more typical of a troubled insurer than a tech-enabled ACA platform. That mismatch is exactly what Barclays is leaning into with its $35 target, well ahead of the Street’s mid-$20s view.

For traders, the message is simple: Oscar Health is no longer a sleepy turnaround. It’s a name on multiple radar screens, with OSCR showing strong trend support on the daily chart and clean intraday ranges that favor disciplined entries and exits. The early-June 12%–15% surge showed how quickly this stock can move when upgrades hit the tape and shorts scramble.

At the same time, Wells Fargo’s caution on earnings visibility beyond 2026 and its focus on payment integrity remind traders that this is not a free ride. Execution still matters, and momentum can cut both ways if the story slips. This is where the Tim Sykes mindset applies: “The market rewards preparation, not prediction. Study the pattern, know your levels, and be ready to react.” As millionaire penny stock trader and teacher Tim Sykes says, “It’s not about how much money you make; it’s about how much money you keep.” For OSCR, that means tracking every new analyst note, watching volume like a hawk, and, above all, managing risk first. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”